EXTON, PA — West Pharmaceutical Services, Inc. (NYSE: WST) said it will report fourth-quarter and full-year 2025 financial results before the market opens Thursday, February 12, 2026, setting the stage for a closely watched update from one of the pharmaceutical industry’s key suppliers.
The company said it will follow the earnings release with a conference call at 8:00 a.m. Eastern Time to discuss results and business expectations. A live webcast will be available at https://edge.media-server.com/mmc/p/x6t2nf5a, and a replay will remain accessible on the company’s website for approximately 90 days.
West said a slide presentation accompanying the results will be posted the morning of the call in the Investors section of its website at https://investor.westpharma.com/. Participants wishing to ask questions during the call must register in advance at https://register-conf.media-server.com/register/BIddf085f5668a414e81986e71c1dc1085.
Headquartered in Exton, West is a leading provider of injectable drug delivery solutions and services, supplying components and devices that support the safe containment and delivery of medicines used by established and emerging drug developers worldwide. The company employs more than 10,000 people across 50 global sites, including 25 manufacturing facilities, and delivers more than 41 billion components and devices annually.
In fiscal year 2024, West reported net sales of $2.89 billion. The company is a member of the Standard & Poor’s 500 index.
Investors are expected to focus on demand trends across injectable therapies and West’s outlook for growth as pharmaceutical and biotech companies continue to expand pipelines of complex and high-value medicines.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.